This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Ethics  • Pregnancy and Breast Feeding  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic

Brian Vastag

JAMA. 2004;291:927-929.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington, DC—When Laurie Goldberg Strongin and her husband Allen discovered that their son had a rare genetic disorder, they decided to have another child. Over 3 years and 9 rounds of in vitro fertilization, the couple spent $135 000 in the hopes of conceiving a baby who could save their first son, Henry.

Henry was born in 1995 with Fanconi anemia, a rare, almost universally fatal genetic disorder. The only hope for most patients with the condition is a matched sibling bone marrow transplant, which pushes survival rates to 90%.

The couple's spirits skyrocketed when they heard of a new technology, preimplantation genetic diagnosis (PGD). The procedure, which screens embryos created in vitro for genetic defects and other characteristics, offered a double dose of hope: their next child could be free of Fanconi anemia and provide Henry with bone marrow. (See box on "What is Preimplantation Genetic Diagnosis?")

. . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preimplantation Genetic Diagnosis--An Overview
Ogilvie et al.
J. Histochem. Cytochem. 2005;53:255-260.
ABSTRACT | FULL TEXT